title: The therapeutic potency of HSP65-GTL in GL261 glioma-bearing mice.
abstract: Gliomas are the most common type of brain tumor with poor prognosis. Even after combination treatments including surgery, radiation, and chemotherapy, the median survival is around 15 months, calling for novel approaches such as immunotherapy. To develop novel therapeutic approaches, we tried to prepare a candidate vaccine by mixing the recombinant mycobacterial heat-shock protein 65 (HSP65) with GL261 glioma tissue lysate (GTL). Our data showed that HSP65-GTL induced potent cytotoxic T lymphocyte and prolonged the survival of mice bearing GL261 gliomas. Furthermore, HSP65 or HSP65-GTL upregulated mRNA expressions of RORγt and interleukin-17A in spleen cells or draining lymph node cells, respectively, and enhanced the ratios of brain-infiltrating Th17 cells and inflammatory cells, indicating that the antitumor effect of HSP65-GTL was associated with Th17-type immunity.
authors.affiliation: Departments of *Immunology †Molecular Biology, College of Basic Medical Sciences ‡Department of Hepatobiliary-Pancreatic Surgery, Third Hospital (China-Japan Union Hospital) §Department of Endodontics, School and Hospital of Stomatology, Jilin University, Changchun, China.
authors.forename: Youyou
authors.initials: Y
authors.lastname: Yan
authors.forename: Mingli
authors.initials: M
authors.lastname: Fang
authors.forename: Wei
authors.initials: W
authors.lastname: Xuan
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wu
authors.forename: Xiuping
authors.initials: X
authors.lastname: Meng
authors.forename: Liying
authors.initials: L
authors.lastname: Wang
authors.forename: Yongli
authors.initials: Y
authors.lastname: Yu
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D018834:Chaperonin 60 / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D005260:Female; D005910:Glioma / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D007167:Immunotherapy; D020381:Interleukin-17 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D058504:Th17 Cells / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D001426:Bacterial Proteins; D019496:Cancer Vaccines; D018834:Chaperonin 60; D020381:Interleukin-17; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D011994:Recombinant Proteins; C074119:heat-shock protein 65, Mycobacterium